Due to their unique ability to induce apoptosis in cancer cells in vitro while showing no apparent toxicity to normal cells, recombinant human TRAIL and DR4/5 agonistic antibodies have been widely studied for cancer therapy35. Here, TNFRSF10A is linked to cancer.